176 related articles for article (PubMed ID: 16639484)
1. [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens].
Cuomo G; Molinaro G; La Montagna G; Migliaresi S; Valentini G
Reumatismo; 2006; 58(1):22-5. PubMed ID: 16639484
[TBL] [Abstract][Full Text] [Related]
2. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
[TBL] [Abstract][Full Text] [Related]
4. A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
Smolen JS; Breedveld FC; Schiff MH; Kalden JR; Emery P; Eberl G; van Riel PL; Tugwell P
Rheumatology (Oxford); 2003 Feb; 42(2):244-57. PubMed ID: 12595618
[TBL] [Abstract][Full Text] [Related]
5. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
Aletaha D; Funovits J; Keystone EC; Smolen JS
Arthritis Rheum; 2007 Oct; 56(10):3226-35. PubMed ID: 17907167
[TBL] [Abstract][Full Text] [Related]
6. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
7. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
[TBL] [Abstract][Full Text] [Related]
9. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
10. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
[TBL] [Abstract][Full Text] [Related]
15. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study.
Mandl P; Balint PV; Brault Y; Backhaus M; D'Agostino MA; Grassi W; van der Heijde D; de Miguel E; Wakefield RJ; Logeart I; Dougados M
Arthritis Care Res (Hoboken); 2013 Jun; 65(6):879-87. PubMed ID: 23213004
[TBL] [Abstract][Full Text] [Related]
16. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
[TBL] [Abstract][Full Text] [Related]
17. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
[TBL] [Abstract][Full Text] [Related]
20. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study.
Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K
Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
